Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench / Shitij Kapur en The Canadian Journal of Psychiatry, Año 2000 Vol. 45 - No.3 (Abril)

Público ISBD [artículo]  inThe Canadian Journal of Psychiatry > Año 2000 Vol. 45 - No.3 (Abril) . - pp. 241–246 Título : Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench Tipo de documento: texto impreso Autores: Shitij Kapur, Autor ; Marie Louise Wadenberg, Autor ; Gary Remington, Autor Fecha de publicación: 2022 Artículo en la página: pp. 241–246 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Modelos de enfermedades, Antagonistas de la dopamina, Haloperidol, Racloprida, Estudio en Ratas, Esquizofrenia - terapia farmacológica. Resumen: Animal models are crucial for understanding the mechanism of action of antipsychotics. However, the dose of an antipsychotic in animal studies is often arbitrarily chosen, with haloperidol 1 mg/kg being a rather common standard. Recent clinical positron emission tomography (PET) studies in patients show all antipsychotics to block dopamine D2 receptors, and most are effective at doses that lead to 60% to 80% D2 occupancy. Link: ./index.php?lvl=notice_display&id=29042 [artículo] Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench [texto impreso] / Shitij Kapur, Autor ; Marie Louise Wadenberg, Autor ; Gary Remington, Autor . - 2022 . - pp. 241–246. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Canadian Journal of Psychiatry > Año 2000 Vol. 45 - No.3 (Abril) . - pp. 241–246 Palabras clave: Antipsicóticos, Modelos de enfermedades, Antagonistas de la dopamina, Haloperidol, Racloprida, Estudio en Ratas, Esquizofrenia - terapia farmacológica. Resumen: Animal models are crucial for understanding the mechanism of action of antipsychotics. However, the dose of an antipsychotic in animal studies is often arbitrarily chosen, with haloperidol 1 mg/kg being a rather common standard. Recent clinical positron emission tomography (PET) studies in patients show all antipsychotics to block dopamine D2 receptors, and most are effective at doses that lead to 60% to 80% D2 occupancy. Link: ./index.php?lvl=notice_display&id=29042

The Effects of Valbenazine in Participants with Tardive Dyskinesia / Stewart A. Factor en The Journal of Clinical Psychiatry, Año 2017 - Vol. 78 No.9 ([01/02/2018])

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2017 - Vol. 78 No.9 [01/02/2018] . - pp. 1344-1350 Título : The Effects of Valbenazine in Participants with Tardive Dyskinesia : Results of the 1-Year KINECT 3 Extension Study Tipo de documento: texto impreso Autores: Stewart A. Factor, Autor ; Gary Remington, Autor ; Cynthia L. Comella, Autor Fecha de publicación: 2018 Artículo en la página: pp. 1344-1350 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Valbenazina, Discinesia tardía, Resumen: Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of long-term effects in adults with tardive dyskinesia. Link: ./index.php?lvl=notice_display&id=9783 [artículo] The Effects of Valbenazine in Participants with Tardive Dyskinesia : Results of the 1-Year KINECT 3 Extension Study [texto impreso] / Stewart A. Factor, Autor ; Gary Remington, Autor ; Cynthia L. Comella, Autor . - 2018 . - pp. 1344-1350. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2017 - Vol. 78 No.9 [01/02/2018] . - pp. 1344-1350 Palabras clave: Valbenazina, Discinesia tardía, Resumen: Valbenazine, a highly selective vesicular monoamine transporter 2 inhibitor, is approved for the treatment of tardive dyskinesia. This is the first report of long-term effects in adults with tardive dyskinesia. Link: ./index.php?lvl=notice_display&id=9783

---

1 (1 - 2 / 2)